Subject: AEPP Article Shows Competitive Landscape for Cancer Drugs

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
AEPP Article Shows Competitive Landscape for Cancer Drugs
Hot Stock to WatchHot Stock to Watch

Company: Oncolix, Inc. (Pink Sheets: AEPP)


Price: 0.0772

Change (%): + 0.0225 (41.08)

Volume: 229,187
AEPP Chart

Cancer Research: Compelling and Complex

According to the IMS Institute for Health Informatics, a leading industry data analysis firm, in 2013 92 billion dollars was spent globally by consumers and health insurance companies on cancer drugs. In the coming years, this is expected to increase to well over 100 billion.

How We Got Here

The efforts and results of the Human Genome Project, culminating in the completion of a high-quality sequencing of the entire human genome, pushed the door wide open for today’s cancer research and drug development industry.

The Human Genome Project clarified the structure and organization of the genome and identified many human genes. The project also sequenced the genomes of other species, including the fruit fly and the mouse. This allowed for comparison and identification of the differences and similarities between the genomes of species, a process that helps to uncover the role and functions of particular genes. This comparison has been crucial in figuring out what genes are critical for human life. In addition, and perhaps most importantly, the data was made freely available through the Internet, allowing researchers from all over the world to confidently move forward with drug development research, among many other projects.

When it comes to cancer research, the further studying of the base genome has allowed researchers to uncover driver mutations. These are the mechanisms which drive the increased mutation rate of cancer cells, resulting in tumor growth and the formation of metastases. In addition, researchers have learned that though some mutations are not drivers of this process, some are absolutely crucial to the growth and survival of cancer cells, allowing for research into more targeted therapies.

Oncolix (AEPP)

Oncolix is a relatively new player in the cancer drug research field, but one that began with already promising results, partners, and management. After a reverse merger with publicly held AEPP, Oncolix is now a publicly traded emerging player in the industry. Oncolix is a clinical-stage biotechnology company developing Prolanta™ for the treatment of ovarian, uterine, breast and other cancers. Oncolix began Phase I clinical trials in 2016 for the drug’s first indication, treatment of ovarian cancer patients. There are strong indications for its applicability to other solid tumor indications, including breast, prostrate, and other cancers. In addition, Prolanta has been approved for an orphan drug designation for the treatment of ovarian cancer, which should lead to decreased cost-to-market, federal tax credits and marketing exclusivity. Oncolix has strong collaborative ties with the University of Texas MD Anderson Cancer Center. Michael T. Redman, who has been with Oncolix since 2007 is CEO of the Houston based company. The company currently has a market value of 7.4 million.

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks